Preliminary results of a Neoadjuvant combo-immunotherapy with ipilimumab and nivolumab in locally advanced or limited metastatic melanoma

被引：0
|
作者：
Ferrucci, Pier Francesco [1 ]
Pala, Laura [1 ]
Conforti, Fabio [1 ]
Nezi, Luigi [2 ]
Manzo, Teresa [2 ]
Cocorocchio, Emilia [1 ]
机构：
[1] European Inst Oncol, Melanoma Unit, Milan, Italy
[2] European Inst Oncol, Dept Expt Oncol, Milan, Italy
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
15
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab
    Krueger, Oskar
    Eisenburger, Robin
    Tasdogan, Alpaslan
    Zimmer, Lisa
    Livingstone, Elisabeth
    Hadaschik, Eva
    Theurer, Sarah
    Brodin, Berthold
    Schadendorf, Dirk
    Ugurel, Selma
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
    Levine, Lauren S.
    Mahuron, Kelly M.
    Tsai, Katy K.
    Wu, Clinton
    Mattis, Daiva M.
    Pauli, Mariela L.
    Oglesby, Arielle
    Lee, James C.
    Spitzer, Matthew H.
    Krummel, Matthew F.
    Algazi, Alain P.
    Rosenblum, Michael D.
    Alvarado, Michael
    Daud, Adil, I
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (11) : 4122 - 4130
  • [23] Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer
    Trojan, Jorg
    Stintzing, Sebastian
    Haase, Oliver
    Koch, Christine
    Ziegler, Paul
    Demes, Melanie
    Jelas, Ivan
    ONCOLOGIST, 2021, 26 (12): : E2110 - E2114
  • [24] SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
    Ascierto, P. A.
    Mandala, M.
    Ferrucci, P. F.
    Rutkowski, P.
    Guidoboni, M.
    Fernandez, A. M. Arance
    Ferraresi, V.
    Maiello, E.
    Guida, M.
    Del Vecchio, M.
    Fierro, M. T.
    Queirolo, P.
    Lebbe, C.
    Helgadottir, H.
    Melero, I.
    Palmieri, G.
    Giannarelli, D.
    Grimaldi, A. M.
    Dummer, R.
    Sileni, V. Chiarion
    ANNALS OF ONCOLOGY, 2021, 32 : S1316 - S1317
  • [25] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
    Reddy, Sangeetha M.
    Amaria, Rodabe N.
    Spencer, Christine N.
    Tetzlaff, Michael
    Reuben, Alexandre
    Andrews, Miles
    Wang, Linghua
    Woodman, Scott
    Zhu, Haifeng
    Blando, Jorge
    Vence, Luis
    Zhang, Shaojun
    Jiang, Hong
    Gopalakrishnan, Vancheswaran
    Hudgens, Courtney
    Wani, Khalida
    Tawbi, Hussein
    Diab, Adi
    Glitza, Isabella
    Patel, Sapna
    Hwu, Wen-Jen
    Wong, Michael
    Hwu, Patrick
    Cormier, Janice
    Lucci, Anthony
    Royal, Richard
    Lee, Jeffrey E.
    Simpson, Lauren
    Burton, Elizabeth M.
    Gershenwald, Jeffrey E.
    Ross, Merrick
    Allison, James
    Sharma, Padmanee
    Davies, Michael
    Wargo, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [26] Immuno-mediated Bullous Pemphigoid with Mucous Membrane Exposure by combined Immunotherapy with Nivolumab and Ipilimumab in metastatic Melanoma
    Wilhelmi, J.
    Koechel, A.
    Garbe, C.
    Lomberg, D.
    Meiwes, A.
    Tampouri, I
    Thomas, I
    Eigentler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 27 - 28
  • [27] Temporary Elevation of S100 Titre in Autoimmune Hypophysitis with combined Immunotherapy with Nivolumab and Ipilimumab for metastatic Melanoma
    Koechel, A.
    Wilhelmi, J.
    Meiwes, A.
    Garbe, C.
    Eigentler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 37 - 37
  • [28] Neoadjuvant Immunotherapy with Ipilimumab/Nivolumab leads to a complete Response of a primary malignant Melanoma in an 89-year-old Patient
    Spahn, P.
    Klemke, C. D.
    Schweiger, T.
    Buchholz, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 20 - 21
  • [29] A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
    Najjar, Yana
    McCurry, Dustin
    Lin, Huang
    Lin, Yan
    Davar, Diwakar
    Drabick, Joseph J.
    Neves, Rogerio Izar
    Ernstoff, Marc S.
    Puzanov, Igor
    Skitzki, Joseph J.
    Pingpank, James F.
    Holtzman, Matthew Peter
    Sander, Cindy
    Rose, Amy
    Kirkwood, John M.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
    Myrdal, Caitlyn N.
    Sundararajan, Srinath
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
12345